Neos Therapeutics Announces Closing of Initial Public Offering and Exercise of Underwriters’ Over-Allotment Option

DALLAS & FORT WORTH, Texas--(BUSINESS WIRE)-- Neos Therapeutics, Inc. (NASDAQ: NEOS) (“Neos” or “the Company”) today announced the closing of its initial public offering of 5,520,000 shares of its common stock at an initial public offering price of $15.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 720,000 additional shares of common stock. All of the shares in the offering were offered by Neos. The shares of Neos’ common stock began trading on the NASDAQ Global Market on July 23, 2015 under the ticker symbol “NEOS.” Including proceeds from the sale of the additional shares subject to the underwriters’ option, the gross proceeds from the initial public offering were $82.8 million, before deducting underwriting discounts and commissions and offering expenses.

UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as joint book-running managers and JMP Securities acted as a lead manager for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 22, 2015. This offering was made solely by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from the offices of UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, or by telephone: (888) 827-7275; BMO Capital Markets Corp., 3 Times Square, New York, NY 10036, Attention: Equity Syndicate Department, Telephone: (800) 414-3627, Email: [email protected]; or RBC Capital Markets, LLC, Attention: Prospectus Department, 200 Vesey Street, 8th Floor, New York, NY 10281.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Neos Therapeutics

Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified‐release drug delivery technology platform. The Company is initially focusing on ADHD and has developed three branded product candidates that are XR medications in patient‐friendly ODT or liquid suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®, an XR liquid suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150728006664/en/

Neos Therapeutics
Vipin K. Garg, 919-434‐6643
Chief Executive Officer, President and Director
[email protected]
or
Richard I. Eisenstadt, 972-408‐1389
Chief Financial Officer
[email protected]
or
Lazar Partners
David Carey, 212-867‐1768
Investor Relations
[email protected]

Source: Neos Therapeutics, Inc.

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• Greenwave Technology Solutions (GWAV) Strengthens Balance Sheet
• Ancora Sends Important Letter to Fellow Shareholders About Our Collective Opportunity to Transform and Turn Around Norfolk Southern (NSC)